Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck

Head and Neck

Volumn 36, Issue 11, 2014, Pages 1619-1627

  Kurisetty, Vittal V S ^a,c   Heiber, Joshua ^a,d   Myers, Rae ^b   Pereira, Guilherme S ^a,e   Goodwin, Jarrard W ^a   Federspiel, Mark J ^b   Russell, Stephen J ^b   Peng, Kah Whye ^b   Barber, Glen ^a   Merchan, Jaime R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

biodistribution; preclinical studies; squamous cell carcinoma; syngeneic models; vesicular stomatitis virus

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS EXPRESSING INTERFERON BETA; VIRUS ANTIBODY; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HYPOXIA; IMMUNOCOMPETENCE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL; VIRUS REPLICATION; ANALYSIS OF VARIANCE; ANIMAL; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FISCHER 344 RAT; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOLOGY; ISOGRAFT; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; NONPARAMETRIC TEST; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; RANDOMIZATION; RAT; SAFETY; TREATMENT OUTCOME; TUMOR CELL CULTURE; VESICULAR STOMATITIS; VESICULOVIRUS; VIROLOGY; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCOMPETENCE; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MICE; ONCOLYTIC VIROTHERAPY; RANDOM ALLOCATION; RATS; RATS, INBRED F344; SAFETY; STATISTICS, NONPARAMETRIC; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VESICULAR STOMATITIS; VESICULOVIRUS;

EID: 84933524463     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23502     Document Type: Conference Paper

References (37)

1. Porosnicu M, Mian A, Barber GN,. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 2003; 63: 8366-8376.
2. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
3. Shin DM, Khuri FR,. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2013; 35: 443-453.
4. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA,. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012; 48: 1191-1201.
5. de Andrade DA, Machiels JP,. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr Opin Oncol 2012; 24: 211-217.
6. Bourhis J, Le Maître A, Baujat B, et al., Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19: 188-194.
7. Brockstein B, Haraf DJ, Rademaker AW, et al., Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15: 1179-1186.
8. Posner MR, Hershock DM, Blajman CR, et al., Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
9. Salama JK, Seiwert TY, Vokes EE,. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25: 4118-4126.
10. Liu TC, Galanis E, Kirn D,. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117.
11. Eager RM, Nemunaitis J,. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18: 305-317.
12. Barber GN,. VSV-tumor selective replication and protein translation. Oncogene 2005; 24: 7710-7719.
13. Shin EJ, Chang JI, Choi B, et al., Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg 2007; 136: 811-817.
14. Shin EJ, Wanna GB, Choi B, et al., Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007; 117: 210-214.
15. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ,. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope 2008; 118: 237-242.
16. Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA,. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 2006; 28: 239-253.
17. Johnson JE, Nasar F, Coleman JW, et al., Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007; 360: 36-49.
18. Obuchi M, Fernandez M, Barber GN,. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003; 77: 8843-8856.
19. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ,. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17: 550-558.
20. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J,. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33: 121-128.
21. Jenks N, Myers R, Greiner SM, et al., Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 2010; 21: 451-462.
22. Majid AM, Ezelle H, Shah S, Barber GN,. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol 2006; 80: 6993-7008.
23. Fernandez M, Porosnicu M, Markovic D, Barber GN,. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904.
24. Elsby R, Heiber JF, Reid P, Kimball SR, Pavitt GD, Barber GN,. The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus. J Virol 2011; 85: 9716-9725.
25. Balachandran S, Barber GN,. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004; 5: 51-65.
26. Merchan JR, Kovács K, Railsback JW, et al., Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One 2010; 5: e13699.
27. Heiber JF, Barber GN,. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol 2011; 85: 10440-10450.
28. Hadac EM, Peng KW, Nakamura T, Russell SJ,. Reengineering paramyxovirus tropism. Virology 2004; 329: 217-225.
29. Ebert O, Shinozaki K, Kournioti C, Park MS, García-Sastre A, Woo SL,. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64: 3265-3270.
30. Shin EJ, Wanna GB, Choi B, et al., Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007; 117: 210-214.
31. Wu Y, Lun X, Zhou H, et al., Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 2008; 14: 1218-1227.
32. Goel A, Carlson SK, Classic KL, et al., Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110: 2342-2350.
33. Wu L, Huang TG, Meseck M, et al., rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther 2008; 19: 635-647.
34. Ramsburg E, Publicover J, Buonocore L, et al., A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 2005; 79: 15043-15053.
35. Brizel DM, Dodge RK, Clough RW, Dewhirst MW,. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-117.
36. Nordsmark M, Bentzen SM, Rudat V, et al., Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
37. Rajendran JG, Schwartz DL, O'Sullivan J, et al., Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-5441.